NCT06921928

Study for AZD4360 in Participants With Advanced Solid Tumours

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2025-04-29Est. Completion: 2027-03-31

Enrollment target: 117 participants

Locations

Research Site, Santa Monica, California, United States
Research Site, Providence, Rhode Island, United States
Research Site, Houston, Texas, United States
Research Site, Beijing, China
Research Site, Chengdu, China
Research Site, Shanghai, China
Research Site, Wuhan, China
Research Site, Berlin, Germany
Research Site, Dresden, Germany
Research Site, Frankfurt, Germany
Research Site, Chūōku, Japan
Research Site, Kashiwa, Japan
Research Site, Kōtoku, Japan
Research Site, Sendai, Japan
Research Site, Glasgow, United Kingdom
Research Site, Leeds, United Kingdom
Research Site, London, United Kingdom
Research Site, Oxford, United Kingdom

Other microbiome trials you might be interested in

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerPhase 3Recruiting

HER2-positive Gastric CancerGastroesophageal Junction Adenocarcinoma

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and …

Anchorage, United StatesEst. completion Apr 27, 2029

View Trial →

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse EventsRecruiting

Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.